BioCentury
ARTICLE | Clinical News

Androderm testosterone skin patch: Phase II; marketed

July 6, 1998 7:00 AM UTC

A 12-week trial of Androderm showed a 1.34 kg increase in lean body mass compared to no increase with placebo in HIV-infected men, with a greater reduction in fat mass in the treated group versus placebo. However, the differences were not statistically significant, nor did changes in quality of life scores correlate with testosterone treatment.

Weight gain also was seen in women with AIDS wasting given a lower-dose testosterone patch in a 12-week trial. Statistical significance was achieved in weight gain with a single patch delivering a dose equivalent to normal hormone levels (p=0.043), but not with two patches (p=0.263). Further, 5 of 6 amenorrheic patients given the lower dose resumed menses compared to 1 of 4 in the high dose group. ...